Unilife scores Premier contract

York, PA-based Unilife ($UNIS) has been awarded a two-year contract by Premier Purchasing Partners for the supply of its Unitract 1-mL safety syringes. Premier provides group contracting to more than 2,500 U.S. hospitals and over 76,000 healthcare sites nationwide.

"Our Unitract 1mL safety syringes, which are designed for use when drawing medication from a vial or ampoule, can provide optimal protection to healthcare workers and others at risk of infection from needlestick injuries," said Alan Shortall, CEO of Unilife. "Unitract represents the first and only known range of insulin and tuberculin syringes with automatic, operator-controlled needle retraction features that are fully integrated within the syringe."

Unilife has been in the news a lot this year. In the spring, Unilife began a scheduled realignment of its operations, which included "redundant positions across various levels of the organization," to save $12 million. The effort came as the company started focusing on the production and sale of its Unifill prefilled syringe, the Unitract 1-mL syringe and the commercialization of other pipeline products.

Since its realignment announcement, it also has launched a line of auto-injectors are meant for the rising numbers of patients who inject themselves outside a healthcare setting. In addition, it began initial sales of its Unifill ready-to-fill syringes to an undisclosed "U.S.-based global pharmaceutical company."

- see the Unilife release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.